Revenue: As of FY2026 Q2, the actual value is USD 65.63 B, beating the estimate of USD 65.24 B.EPS: As of FY2026 Q2, the actual value is USD 1.97, beating the estimate of USD 1.92.EBIT: As of FY2026 Q2, the actual value is USD 795 M.<h3>Financial Performance Summary (Second Quarter Fiscal Year 2026)</h3><h4>Overall Performance</h4><ul><li>GAAP Operating Earnings: Increased 29% to $707 million, compared to $549 million in Q2 FY25.</li><li>Non-GAAP Operating Earnings: Increased 38% to $877 million, up from $635 million in Q2 FY25.</li><li>Net Earnings Attributable to Cardinal Health, Inc. (GAAP): Increased 17% to $467 million, from $400 million in Q2 FY25.</li><li>Non-GAAP Net Earnings Attributable to Cardinal Health, Inc.: Increased 33% to $624 million, from $468 million in Q2 FY25.</li><li>Gross Margin (GAAP): Rose 23% to $2,397 million, from $1,941 million in Q2 FY25.</li><li>Distribution, Selling, General and Administrative Expenses (GAAP): Increased 15% to $1,504 million, from $1,306 million in Q2 FY25.</li><li>Interest Expense, Net (GAAP): Was $88 million, compared to $35 million in Q2 FY25.</li><li>Provision for Income Taxes (GAAP): Increased 45% to $159 million, from $110 million in Q2 FY25.</li><li>Effective Tax Rate (GAAP): Was 25.2%, compared to 21.4% in Q2 FY25.</li><li>Non-GAAP Effective Tax Rate: Remained at 21.4% for both Q2 FY26 and Q2 FY25.</li><li>Weighted-Average Number of Common Shares Outstanding (Diluted): Decreased to 237 million, from 243 million in Q2 FY25.</li></ul><h4>Segment Performance (Second Quarter Fiscal Year 2026)</h4><ul><li>Pharmaceutical and Specialty Solutions:<ul><li>Segment Profit: Increased 29% to $687 million, driven by contributions from brand and specialty products, MSO platforms acquisition, and positive generics program performance.</li><li>Segment Profit Margin: Was 1.13%, up from 1.04% in Q2 FY25.</li></ul></li><li>Global Medical Products and Distribution:<ul><li>Segment Profit: Increased 106% to $37 million, driven by growth from existing customers and cost optimization initiatives, partially offset by tariffs.</li><li>Segment Profit Margin: Was 1.14%, up from 0.57% in Q2 FY25.</li></ul></li><li>Other (includes Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics):<ul><li>Segment Profit: Increased 52% to $179 million, driven by growth across the three operating segments.</li><li>Segment Profit Margin: Was 10.38%, up from 9.20% in Q2 FY25.</li></ul></li></ul><h4>Cash Flow (Second Quarter Fiscal Year 2026)</h4><ul><li>Net Cash Provided by Operating Activities: Was $686 million, compared to net cash used in operating activities of -$396 million in Q2 FY25.</li><li>Net Cash Used in Investing Activities: Was -$1,980 million, compared to -$976 million in Q2 FY25.</li><li>Net Cash Provided by/(Used in) Financing Activities: Was -$519 million, compared to $2,327 million in Q2 FY25.</li><li>Non-GAAP Adjusted Free Cash Flow: Was $543 million, compared to -$250 million in Q2 FY25.</li></ul><h3>Financial Performance Summary (Year-to-Date Fiscal Year 2026)</h3><h4>Overall Performance</h4><ul><li>GAAP Operating Earnings: Increased 23% to $1,375 million, compared to $1,117 million in YTD FY25.</li><li>Non-GAAP Operating Earnings: Increased 38% to $1,734 million, up from $1,260 million in YTD FY25.</li><li>Net Earnings Attributable to Cardinal Health, Inc. (GAAP): Increased 12% to $917 million, from $816 million in YTD FY25.</li><li>Non-GAAP Net Earnings Attributable to Cardinal Health, Inc.: Increased 33% to $1,235 million, from $927 million in YTD FY25.</li><li>Gross Margin (GAAP): Rose 23% to $4,716 million, from $3,843 million in YTD FY25.</li><li>Distribution, Selling, General and Administrative Expenses (GAAP): Increased 15% to $2,965 million, from $2,583 million in YTD FY25.</li><li>Interest Expense, Net (GAAP): Was $168 million, compared to $67 million in YTD FY25.</li><li>Provision for Income Taxes (GAAP): Increased 29% to $303 million, from $234 million in YTD FY25.</li><li>Effective Tax Rate (GAAP): Was 24.7%, compared to 22.2% in YTD FY25.</li><li>Non-GAAP Effective Tax Rate: Was 21.7%, compared to 22.2% in YTD FY25.</li><li>Weighted-Average Number of Common Shares Outstanding (Diluted): Decreased to 238 million, from 243 million in YTD FY25.</li></ul><h4>Segment Performance (Year-to-Date Fiscal Year 2026)</h4><ul><li>Pharmaceutical and Specialty Solutions:<ul><li>Segment Profit: Increased 28% to $1,354 million.</li><li>Segment Profit Margin: Was 1.13%, up from 1.07% in YTD FY25.</li></ul></li><li>Global Medical Products and Distribution:<ul><li>Segment Profit: Showed significant growth to $83 million.</li><li>Segment Profit Margin: Was 1.29%, up from 0.41% in YTD FY25.</li></ul></li><li>Other:<ul><li>Segment Profit: Increased 55% to $345 million.</li><li>Segment Profit Margin: Was 10.25%, up from 8.99% in YTD FY25.</li></ul></li></ul><h4>Cash Flow (Year-to-Date Fiscal Year 2026)</h4><ul><li>Net Cash Provided by Operating Activities: Was $1,659 million, compared to net cash used in operating activities of -$2,043 million in YTD FY25.</li><li>Net Cash Used in Investing Activities: Was -$2,122 million, compared to -$1,064 million in YTD FY25.</li><li>Net Cash Provided by/(Used in) Financing Activities: Was -$629 million, compared to $1,787 million in YTD FY25.</li><li>Non-GAAP Adjusted Free Cash Flow: Was $1,828 million, compared to -$1,611 million in YTD FY25.</li></ul><h3>Outlook / Guidance (Fiscal Year 2026)</h3>Cardinal Health (卡地纳健康) raised its fiscal year 2026 non-GAAP diluted EPS guidance to a range of $10.15 to $10.35, reflecting a 23% to 26% growth. This guidance includes raised and narrowed Pharmaceutical and Specialty Solutions segment profit growth to 20% to 22%, Global Medical Products and Distribution segment profit raised to approximately $150 million, and Other segment profit growth raised to 33% to 35%. Additionally, the non-GAAP effective tax rate is decreased to 21% to 23%, and diluted weighted average shares outstanding are decreased to 237 million to 238 million.<h3>Other Key Metrics</h3><ul><li>Share Repurchase: Cardinal Health (卡地纳健康) completed an additional $375 million accelerated share repurchase program in Q2 FY26, bringing year-to-date share repurchases to $750 million.</li><li>Leverage: Cardinal Health (卡地纳健康) reached its targeted leverage range of 2.75x to 3.25x Adjusted Debt to EBITDA, achieving 3.2x leverage as of December 31, 2025.</li><li>Acquisitions: The Specialty Alliance platform completed the acquisition of Solaris Health, a leading Urology MSO, on November 3rd.</li><li>Product/Service Initiatives: The at-Home Solutions business introduced the ContinuCare™ Pathway program and announced a partnership with Publix Super Markets Inc.</li></ul>

Cardinal Health | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 65.63 B